ContraFect 将来の成長

Future 基準チェック /06

現在、 ContraFectの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Biotechs 収益成長	28.5%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	09 Nov 2023

今後の成長に関する最新情報

Recent updates

Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?

Mar 09

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

Jan 15

What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?

Nov 24

Contrafect EPS beats by $0.16

Nov 13

業績と収益の成長予測

OTCPK:CFRX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	N/A	N/A	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
12/31/2023	N/A	N/A	N/A	N/A	1
9/30/2023	N/A	-24	-36	-36	N/A
6/30/2023	N/A	-36	-37	-37	N/A
3/31/2023	N/A	-46	-43	-43	N/A
12/31/2022	N/A	-65	-46	-46	N/A
9/30/2022	N/A	-60	-45	-45	N/A
6/30/2022	N/A	-48	-46	-46	N/A
3/31/2022	N/A	-35	-44	-44	N/A
12/31/2021	N/A	-20	-41	-41	N/A
9/30/2021	N/A	-22	-40	-40	N/A
6/30/2021	N/A	-14	-37	-37	N/A
3/31/2021	N/A	-26	-35	-35	N/A
12/31/2020	N/A	-28	-33	-33	N/A
9/30/2020	N/A	-32	-33	-33	N/A
6/30/2020	N/A	-41	-29	-29	N/A
3/31/2020	N/A	-32	-28	-28	N/A
12/31/2019	N/A	-13	-27	-27	N/A
9/30/2019	N/A	3	-27	-27	N/A
6/30/2019	N/A	4	-29	-29	N/A
3/31/2019	N/A	-7	-27	-27	N/A
12/31/2018	N/A	-38	-26	-26	N/A
9/30/2018	N/A	-48	-25	-25	N/A
6/30/2018	N/A	-46	-25	-25	N/A
3/31/2018	N/A	-28	-25	-25	N/A
12/31/2017	N/A	-16	-25	-25	N/A
9/30/2017	N/A	-10	-27	-27	N/A
6/30/2017	N/A	-19	N/A	-29	N/A
3/31/2017	N/A	-26	N/A	-29	N/A
12/31/2016	N/A	-29	N/A	-29	N/A
9/30/2016	N/A	-37	N/A	-27	N/A
6/30/2016	N/A	-32	N/A	-25	N/A
3/31/2016	N/A	-29	N/A	-24	N/A
12/31/2015	N/A	-25	N/A	-22	N/A
9/30/2015	N/A	-22	N/A	-20	N/A
6/30/2015	N/A	-33	N/A	-20	N/A
3/31/2015	N/A	-34	N/A	-17	N/A
12/31/2014	N/A	-35	N/A	-15	N/A
9/30/2014	N/A	-41	N/A	-14	N/A
6/30/2014	N/A	-29	N/A	-12	N/A
3/31/2014	N/A	-24	N/A	-13	N/A
12/31/2013	N/A	-24	N/A	-14	N/A
9/30/2013	N/A	-19	N/A	-15	N/A
6/30/2013	N/A	-20	N/A	-16	N/A
3/31/2013	N/A	-20	N/A	-17	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CFRXの予測収益成長が貯蓄率 ( 2.2% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: CFRXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: CFRXの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: CFRXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: CFRX来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CFRXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

ContraFect 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased to US$2.00

No longer forecast to breakeven

Price target decreased to US$13.00

Price target decreased to US$13.00

Price target decreased to US$13.00

Forecast to breakeven in 2024

Recent updates

ContraFect Corporation Filed for Bankruptcy

ContraFect Corporation Announces Chief Executive Officer Changes

ContraFect Receives Determination Letter from the Nasdaq Hearings Advisor to Delist its Common Stock from the Nasdaq Capital Market

ContraFect Receives Non Compliance Notice from Nasdaq

Nasdaq Determines to Delist ContraFect's Common Stock from The Nasdaq Capital Market Due to Non-Compliance with Minimum Stockholders' Equity Requirement

ContraFect Corporation Presents Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company's Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-Neg Pathogens

ContraFect Announces Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Nasdaq Determines to Deny ContraFect's Request for Continued Listing on the Nasdaq Capital Market

ContraFect Corporation Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase

ContraFect Corporation Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections

Price target decreased to US$2.00

ContraFect Receives Non-Compliance Letter from Nasdaq

Contrafect Corporation Announces Resignation of Cara Cassino as Chief Medical Officer and Executive Vice President of Research and Development

Contrafect GAAP EPS of -$0.46 misses by $0.13

No longer forecast to breakeven

Contrafect Announces Independent Dsmb Recommends Exebacase Phase 3 Disrupt Study Be Stopped for Futility Following Interim Analysis

ContraFect sinks ~76% as data safety board recommends ending co's DISRUPT trial

ContraFect (NASDAQ:CFRX) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$13.00

ContraFect Corporation, Annual General Meeting, May 17, 2022

Price target decreased to US$13.00

Price target decreased to US$13.00

Forecast to breakeven in 2024

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market

We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate

ContraFect Corporation(NasdaqCM:CFRX) dropped from Russell 3000E Growth Index

Forecast to breakeven in 2024

Price target decreased to US$15.90

Is ContraFect (NASDAQ:CFRX) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

ContraFect Corporation Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook

Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?

New 90-day low: US$4.81

ContraFect Corporation Appoints Jane F. Barlow to its Board of Directors

New 90-day low: US$4.96

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

New 90-day low: US$5.09

New 90-day high: US$5.87

What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?

Contrafect EPS beats by $0.16

Analysts update estimates

ContraFect Corporation announced that it has received $3 million in funding from Pfizer Inc.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘